Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck : a Multicentre Phase II Study

NCT02558387 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT02558387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02558387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck : a Multicentre Phase II Study
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2014
Completion date
January 31, 2017
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or metastatic salivary gland cancer of the head and neck